ORIGINAL PAPER
Frequency and associations of chronic kidney disease among gout patients from a University Teaching Hospital in Nigeria
Submission date: 2017-12-19
Final revision date: 2018-02-05
Acceptance date: 2018-02-26
Online publication date: 2018-02-28
Publication date: 2018-02-28
Reumatologia 2018;56(1):17-23
KEYWORDS
TOPICS
ABSTRACT
Objectives:
To highlight common precipitants and co-morbidities of gout in Nigerians; determine the frequency of chronic kidney disease (CKD) in Nigerian gout patients, as well as identify significant associations of CKD in gout patients.
Material and methods:
Retrospective cross-sectional study of gout cases seen at the Rheumatology Clinic of the Lagos State University Teaching Hospital over five years from January 2011 to December 2015. Gout was diagnosed using the 1977 American Rheumatism Association (ARA) criteria. Clinical and laboratory data were extracted and examined for the presence of CKD defined using Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines as estimated glomerular filtration rate (eGFR, CKD-EPI) < 60 mls/min/1.73 m2 body surface area for > 3 months.
Results:
One hundred and six gout patients were identified representing 4.5% out of a total of 2330 cases seen during the study period. There were 94 males and 12 females. Oligoarthritis was most frequent (41.5%) with the knee mostly affected (20.1%). Diuretic use was the most frequent precipitant (37.9%) with hypertension the commonest co-morbidity (62.9%). Of 70 patients with complete results, 29 had eGFR (CKD-EPI) < 60 mls/min (41.4%). Age, proteinuria, body mass index (BMI) and packed cell volume (PCV) were significant associations of CKD. Gout patients with CKD were significantly older (61.79 vs. 54.41 years, p = 0.003) with a significantly higher proportion developing proteinuria (15 vs. 4 patients, p 0.0001) compared to those without CKD. In contrast, those with CKD had a significantly lower BMI (27.31 vs. 29.65 kg/m2, p = 0.026) and PCV (31.97 vs. 37.95%, p = 0.005).
Conclusions:
Thiazide diuretic use is the most common precipitant while hypertension is the commonest comorbidity in Nigerian gout patients. About two in five Nigerian gout patients had chronic kidney disease at presentation with age, proteinuria, BMI and PCV as significant associations. It is thus imperative to screen for chronic kidney disease when managing gout patients.
To highlight common precipitants and co-morbidities of gout in Nigerians; determine the frequency of chronic kidney disease (CKD) in Nigerian gout patients, as well as identify significant associations of CKD in gout patients.
Material and methods:
Retrospective cross-sectional study of gout cases seen at the Rheumatology Clinic of the Lagos State University Teaching Hospital over five years from January 2011 to December 2015. Gout was diagnosed using the 1977 American Rheumatism Association (ARA) criteria. Clinical and laboratory data were extracted and examined for the presence of CKD defined using Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines as estimated glomerular filtration rate (eGFR, CKD-EPI) < 60 mls/min/1.73 m2 body surface area for > 3 months.
Results:
One hundred and six gout patients were identified representing 4.5% out of a total of 2330 cases seen during the study period. There were 94 males and 12 females. Oligoarthritis was most frequent (41.5%) with the knee mostly affected (20.1%). Diuretic use was the most frequent precipitant (37.9%) with hypertension the commonest co-morbidity (62.9%). Of 70 patients with complete results, 29 had eGFR (CKD-EPI) < 60 mls/min (41.4%). Age, proteinuria, body mass index (BMI) and packed cell volume (PCV) were significant associations of CKD. Gout patients with CKD were significantly older (61.79 vs. 54.41 years, p = 0.003) with a significantly higher proportion developing proteinuria (15 vs. 4 patients, p 0.0001) compared to those without CKD. In contrast, those with CKD had a significantly lower BMI (27.31 vs. 29.65 kg/m2, p = 0.026) and PCV (31.97 vs. 37.95%, p = 0.005).
Conclusions:
Thiazide diuretic use is the most common precipitant while hypertension is the commonest comorbidity in Nigerian gout patients. About two in five Nigerian gout patients had chronic kidney disease at presentation with age, proteinuria, BMI and PCV as significant associations. It is thus imperative to screen for chronic kidney disease when managing gout patients.
REFERENCES (30)
2.
Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516.
3.
Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990 & 2013; 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211-1259.
4.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63: 3136-3141.
5.
Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008; 67: 960-966.
6.
Winnard D, Wright C, Jackson G, et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J 2012; 126: 53-64.
7.
Adelowo O, Umar A, Oguntona S. Gouty arthritis in Nigerians: clinical and laboratory correlates. African Journal of Rheumatology 2014; 2: 23-28.
8.
Kodio B, Pamanta IS, Sylla C,et al. Step wise approach of gout in the Rheumatology ward of Point-G University Teaching Hospital of Bamako, Mali. African Journal of Rheumatology 2015; 3: 22-26.
9.
Cassim B, Mody GM, Deenadayalu VK, Hammond MG. Gout in black South Africans: a clinical and genetic study. Ann Rheum Dis 1994; 53: 759-762.
10.
Oguntona SA. Gout and Its Comorbidity among Nigerians. J Med Biol Sci 2013; 3: 26-32.
11.
Sattui SE, Singh JA, Gaffo AL. Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North Am 2014; 40: 251-278.
12.
Global KDI, Group OKCW. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter 2013; Suppl 2013;3: 1-150.
13.
Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther 2015; 17: 90.
14.
Stanifer JW, Jing B, Tolan S, et al. The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. The Lancet Global Health 2014; 2: e174-e181.
15.
Afolabi MO, Abioye-Kuteyi EA, Arogundade FA, Bello IS. Prevalence of chronic kidney disease in a Nigerian family practice population. South African Family Practice 2009; 51: 132-137.
16.
Akpan EE, Ekrikpo UE, Udo AI. Risk factors for chronic kidney disease in Urban Uyo, South-South, Nigeria. Saudi J Kidney Dis Transpl 2016; 27: 1011-1017.
17.
Fatiu A, Abubakr S, Muzamil H, et al. Undiagnosed hypertension and proteinuria in a market population in Ile-Ife, Nigeria. Arab J Nephrol Transplant 2011; 4: 141-146.
18.
Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 2012; 125: 679-687.
19.
Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
20.
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
21.
Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010; 55: 622.
22.
Uche C, Osegbe I. Comparison of CKD-EPI versus MDRD and Cockcroft-Gault equations to estimate glomerular filtration rate among stable homozygous sickle cell patients in Southwest Nigeria. Nigerian Journal of Clinical Practice 2017; 20: 816-821.
23.
Organization WHO. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation 1999; [publ. no. WHO/NCD/NCS/99.2].
24.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143-3145.
25.
Oyoo G. Gout in patients attending a rheumatology clinic in Nairobi, Kenya. Health Line 2004; 8: 37-38.
26.
Tikly M, Bellingan A, Lincoln D, Russell A. Risk factors for gout: a hospital-based study in urban black South Africans. Rev Rhum Engl Ed 1998; 65: 225-231.
27.
Mijiyawa M, Oniankitan O. Risk factors for gout in Togolese patients. Joint Bone Spine 2000; 67: 441-445.
28.
Fuldeore MJ, Riedel AA, Zarotsky V, et al. Chronic kidney disease in gout in a managed care setting. BMC Nephrol 2011; 12: 36.
29.
Cheyoe N Kuning M, Lim A. The prevalence of Chronic Kidney Disease among gout patients in Nongjik Hospital, Pattani province. Thai Journal of Pharmaceutical Sciences 2012; 36: 144-149.
30.
Shah A, Sundy JS. Predictors of Outcomes in Gout with Comorbid Chronic Kidney Disease. Arthritis Rheum 2011; 63 (Suppl 10): 1034.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
